comparemela.com

Latest Breaking News On - Biocryst pharmaceutical - Page 4 : comparemela.com

Investing in BioCryst Pharmaceuticals (NASDAQ:BCRX) three years ago would have delivered you a 40% gain

By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual.

Financial Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ambrx Biopharma (NYSE:AMAM)

Ambrx Biopharma (NYSE:AMAM – Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Analyst Recommendations This is a summary of recent ratings […]

HC Wainwright Comments on BioCryst Pharmaceuticals, Inc s FY2027 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) – Stock analysts at HC Wainwright decreased their FY2027 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Thursday, May 4th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $1.16 per share for the year, down from […]

Comparing Miromatrix Medical (NASDAQ:MIRO) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

Miromatrix Medical (NASDAQ:MIRO – Get Rating) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends. Risk and Volatility Miromatrix Medical has a beta of […]

Flu season off to a strong and early start, CDC data finds (OTCMKTS:RHHBY)

New data from the CDC found that the flu season has started unusually early this year with a large number of hospitalization due to the virus already as well as one death in a.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.